DZ 002
Alternative Names: DZ-002Latest Information Update: 28 Sep 2024
At a glance
- Originator Da Zen Theranostics
- Class Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for phase-I development in Lymphoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Injection)
- 28 Sep 2024 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Injection)
- 01 Aug 2021 Phase-I clinical trials in Lymphoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in USA (IV) (NCT04970992)